Sumitomo Mitsui Trust Group Inc. Reduces Holdings in Humana Inc. $HUM

Sumitomo Mitsui Trust Group Inc. reduced its holdings in shares of Humana Inc. (NYSE:HUM) by 9.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 298,807 shares of the insurance provider’s stock after selling 32,507 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.25% of Humana worth $73,052,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. ARGA Investment Management LP purchased a new position in Humana during the 2nd quarter valued at about $13,200,000. R Squared Ltd bought a new stake in shares of Humana in the second quarter worth approximately $214,000. Paralel Advisors LLC grew its position in Humana by 39.4% during the second quarter. Paralel Advisors LLC now owns 10,096 shares of the insurance provider’s stock valued at $2,468,000 after buying an additional 2,856 shares during the period. FNY Investment Advisers LLC grew its position in Humana by 38.9% during the second quarter. FNY Investment Advisers LLC now owns 500 shares of the insurance provider’s stock valued at $122,000 after buying an additional 140 shares during the period. Finally, D.A. Davidson & CO. grew its position in Humana by 37.6% during the second quarter. D.A. Davidson & CO. now owns 2,658 shares of the insurance provider’s stock valued at $650,000 after buying an additional 726 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Down 0.2%

Shares of HUM opened at $290.66 on Monday. The company’s fifty day moving average is $281.65 and its 200 day moving average is $258.79. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The stock has a market capitalization of $34.96 billion, a PE ratio of 22.31, a P/E/G ratio of 1.70 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter in the prior year, the firm posted $6.96 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.2%. Humana’s payout ratio is 27.17%.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of recent analyst reports. Guggenheim reiterated a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Bank of America upped their price target on shares of Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a research report on Friday, October 10th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Humana in a research report on Saturday. Wells Fargo & Company upped their price target on shares of Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 7th. Finally, Evercore ISI initiated coverage on shares of Humana in a research report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 price target for the company. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $297.58.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.